secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2022-12-21T23:59:59+00:00
Accession:  0000950170-22-026872
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus Pharma Q3 net loss $8.8M ($0.07/shr); cash $67M; CRB-601 IND on track for mid-2023
--------------------------------------------------------------------------------

- Net loss of $8.8M ($0.07 per share) vs $2.2M loss in Q3 2021; prior year included $12.3M tax credit.
- Operating expenses decreased to $8.2M from $14.0M, driven by lower clinical trial and manufacturing costs.
- Cash and investments $67M; amended debt agreement defers principal payments to September 2023, extending runway.
- CRB-601 pre-clinical data at SITC; IND submission on track for mid-2023.
- Actively exploring partnerships for CRB-913 (CB1 inverse agonist) for obesity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017022026872/0000950170-22-026872-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017022026872/crbp-20221108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-026872

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer